|
Allakos Inc. (ALLK) DCF Valuation
US | Healthcare | Biotechnology | NASDAQ
|
- ✓ Entièrement Modifiable: Adapté À Vos Besoins Dans Excel Ou Sheets
- ✓ Conception Professionnelle: Modèles Fiables Et Conformes Aux Normes Du Secteur
- ✓ Pré-Construits Pour Une Utilisation Rapide Et Efficace
- ✓ Aucune Expertise N'Est Requise; Facile À Suivre
Allakos Inc. (ALLK) Bundle
Discover the true potential of Allakos Inc. (ALLK) with our advanced DCF Calculator! Adjust essential assumptions, explore various scenarios, and evaluate how changes affect Allakos Inc. (ALLK) valuation – all within one convenient Excel template.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Revenue Growth, % | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EBITDA | -91.4 | -155.5 | -269.2 | -315.4 | -189.9 | .0 | .0 | .0 | .0 | .0 |
| EBITDA, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| Depreciation | 1.5 | 2.3 | 4.9 | 10.0 | 6.1 | .0 | .0 | .0 | .0 | .0 |
| Depreciation, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| EBIT | -92.9 | -157.9 | -274.0 | -325.3 | -196.1 | .0 | .0 | .0 | .0 | .0 |
| EBIT, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| Total Cash | 495.9 | 659.0 | 424.2 | 279.8 | 170.8 | .0 | .0 | .0 | .0 | .0 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| Inventories | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Inventories, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| Accounts Payable | 6.0 | 14.0 | 13.7 | 4.8 | 1.8 | .0 | .0 | .0 | .0 | .0 |
| Accounts Payable, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| Capital Expenditure | -.8 | -.6 | -33.2 | -8.3 | -.6 | .0 | .0 | .0 | .0 | .0 |
| Capital Expenditure, % | 100 | 100 | 100 | 100 | 100 | 0 | 0 | 0 | 0 | 0 |
| Tax Rate, % | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EBITAT | -84.5 | -151.8 | -271.3 | -322.8 | -196.1 | .0 | .0 | .0 | .0 | .0 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -77.8 | -142.1 | -299.9 | -330.0 | -193.6 | -1.8 | .0 | .0 | .0 | .0 |
| WACC, % | 7.88 | 7.94 | 7.97 | 7.98 | 7.98 | 7.95 | 7.95 | 7.95 | 7.95 | 7.95 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -1.6 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | 0 | |||||||||
| Terminal Value | 0 | |||||||||
| Present Terminal Value | 0 | |||||||||
| Enterprise Value | -2 | |||||||||
| Net Debt | -25 | |||||||||
| Equity Value | 23 | |||||||||
| Diluted Shares Outstanding, MM | 87 | |||||||||
| Equity Value Per Share | 0.27 |
What You Will Receive
- Comprehensive Financial Model: Allakos Inc.’s actual data provides accurate DCF valuation.
- Complete Forecast Flexibility: Modify revenue growth, profit margins, WACC, and other essential factors.
- Real-Time Calculations: Automatic updates allow you to view results instantly as you adjust inputs.
- Professional-Grade Template: A polished Excel file crafted for high-standard valuation purposes.
- Adaptable and Reusable: Designed for versatility, enabling repeated application for thorough forecasts.
Key Features
- Customizable Forecast Inputs: Adjust essential parameters such as revenue projections, operating margins, and research & development expenses.
- Instant DCF Valuation: Quickly computes intrinsic value, net present value, and additional metrics with ease.
- High-Precision Accuracy: Leverages Allakos Inc.'s (ALLK) actual financial data for dependable valuation results.
- Effortless Scenario Analysis: Explore various assumptions and evaluate results effortlessly.
- Efficiency Booster: Avoid the hassle of constructing intricate valuation models from the ground up.
How It Works
- Step 1: Download the Excel file.
- Step 2: Review pre-entered Allakos Inc. (ALLK) data (historical and projected).
- Step 3: Adjust key assumptions (yellow cells) based on your analysis.
- Step 4: View automatic recalculations for Allakos Inc. (ALLK)’s intrinsic value.
- Step 5: Use the outputs for investment decisions or reporting.
Why Choose Allakos Inc. (ALLK)?
- Innovative Solutions: Cutting-edge therapies aimed at addressing significant unmet medical needs.
- Robust Research: Backed by extensive clinical trials and scientific evidence to support efficacy.
- Patient-Centric Approach: Focused on improving the quality of life for patients through targeted treatments.
- Experienced Team: Led by industry experts with a proven track record in biopharmaceutical development.
- Commitment to Quality: Adherence to the highest standards in research and manufacturing processes.
Who Should Use This Product?
- Investors: Evaluate Allakos Inc.’s (ALLK) valuation before making investment decisions.
- CFOs and Financial Analysts: Enhance valuation methodologies and validate financial forecasts.
- Startup Founders: Understand the valuation strategies applied to biotech companies like Allakos Inc.
- Consultants: Provide detailed valuation analyses and reports for clients in the healthcare sector.
- Students and Educators: Utilize current market data to study and teach valuation principles.
What the Template Contains
- Pre-Filled Data: Contains Allakos Inc.’s historical financials and projections.
- Discounted Cash Flow Model: Editable DCF valuation model featuring automatic calculations.
- Weighted Average Cost of Capital (WACC): A specific sheet for calculating WACC based on user-defined inputs.
- Key Financial Ratios: Assess Allakos Inc.’s profitability, efficiency, and leverage metrics.
- Customizable Inputs: Easily modify revenue growth, margins, and tax rates.
- Clear Dashboard: Visual representations and tables summarizing essential valuation outcomes.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.